IB TraxT

RNS Number : 5309Y

IQ-AI Limited

10 September 2020

 

IQ-AI Ltd

("IQ-AI" or the "Company")

IB Trax™ - the next evolution in brain cancer response assessment

Further building upon its leading position in brain tumour imaging, IQ-AI's subsidiary, Imaging Biometrics (IB), announces the launch its next development initiative, IB Trax. This application will leverage the proven ability of quantitative Delta T1 maps, among other technologies, and focus on an improved workflow for evaluating both brain metastases and primary brain cancer across time. For almost a decade, IB's medical advisors and end-users of IB Neuro have considered that the manually intensive way currently used to longitudinally assess brain lesions is cumbersome and prone to error. IB Trax represents an efficient and streamlined platform that will address a significant and immediate need for routine clinical use.

Metastatic brain tumours are the most common cancers occurring in the brain and result from the spread of primary cancers from sites such as lung, breast, melanoma, colon, and kidney. The American Brain Tumor Association estimates the incidence of brain metastases to be between 200,000 to 300,000 people per year in the United States, approximately ten times the incidence of primary brain tumours. In addition, 10 to 30 percent of people with cancer develop metastatic brain tumours with most having multiple metastases in the brain. Moreover, the overall incidence of metastatic brain disease is increasing, paralleling the rise in primary lung cancer, but also a result of the increased survival rates in patients with metastases.

Key to the management of metastatic disease is the radiologist's assessment of the initial extent of disease followed by routine surveillance to determine if each individual lesion is changing in size and/or if new lesions are present. This represents a tremendous burden for radiologists, because of the frequency of surveillance required, but also because there might exist numerous metastases of various sizes, each changing in different ways over time. The current approach is to manually identify each lesion and then visually assess its growth over time while also keeping track of which lesion(s) have already been assessed. This process is performed for each of the hundreds of high-resolution MR image slices obtained for each patient at each visit. Moreover, current MRIs, and each lesion, must be compared to the MRIs obtained at previous time points. Delta T1 maps, which improve sensitivity to contrast agent enhancement and eliminate confounding signals, will foster rapid and objective delineation of true enhancing regions for radiologists.

Although not as common, high grade primary tumours introduce unique challenges for radiologists. Specifically, new tumour growth often mimics treatment effect on contrast enhanced images. For high grade tumours, IB Trax will leverage the proven technology of IB Neuro which is the only commercially available, tissue validated perfusion method that answers the most important question in neuro oncology today:  "Is the enhancing region showing a tumour or is it an effect due to treatment?"

IB is well-positioned to couple their existing technologies with an improved workflow to systematically identify, quantify, and track primary and metastatic brain lesions. This will reduce measurement variability which should result in more timely treatment decisions. Along with this novel approach for tracking lesion volume, IB Trax will also incorporate traditional approaches for tracking volumes, such as the RECIST criteria.

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

IQ-AI Limited Trevor Brown/Vinod Kaushal/Qu Li Tel: [phone]

Peterhouse Capital Limited (Financial Adviser and Broker) Lucy Williams/Heena Karani Tel: [phone]

ABOUT Imaging Biometrics , LLC

Imaging Biometrics®, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com .

 

END

 

 

STRUKVVRRUUKRAR